This is the authors' abstract. We don't add key points for this paper.
I. SUMMARY OF THE PROBLEM Celiac disease (CD) is an autoimmune condition characterized by an immune-mediated enteropathy of the small intestine. The condition occurs in genetically predisposed individuals who ingest prolamins (alcohol-soluble proteins rich in glutamine and proline) that are found in wheat, rye, and barley. CD produces a spectrum of small intestinal mucosal changes ranging from an increase in the number of intraepithelial lymphocytes to mucosal remodeling with crypt hyperplasia and flattening of the villi. Malabsorption of nutrients is a consequence of the intestinal damage and when prolonged can cause malnutrition. Treatment requires lifelong adherence to a diet that strictly eliminates products containing wheat, rye, and barley. On such a diet, complete recovery of the small intestinal damage can be expected with reversal of nutritional deficits and resolution of symptoms. Historical Aspects Samuel Gee is credited with the first thorough description of the features in children, in 1888. Dietary factors in the pathogenesis were recognized during the 1920s, with Haas describing a clinical cure in patients maintained on a strict banana diet in 1924. During the Second World War, a Dutch pediatrician, Karel Dicke, noticed an association between CD and bread consumption, as symptoms improved during the Dutch famine but relapsed after bread supplies became more plentiful. In collaboration with Van der Kamer, Dicke subsequently showed a relationship between wheat protein ingestion and fat malabsorption in patients with CD, published in his thesis in 1950. With the advent of perioral intestinal mucosal biopsy in the mid 1950s, the characteristic small intestinal mucosal changes were recognized. This led to a realization that CD in childhood was the same condition known as nontropical sprue in adults. The development of serologic tests during the 1970s was an important innovation. These tests provide a reliable means of identifying individuals requiring small intestinal biopsy for definitive diagnosis. Their use in screening various population groups has significantly altered our perception of the clinical manifestations and prevalence of CD. Epidemiology CD has been described throughout the world, including Europe, Russia, the Mediterranean countries, North and South America, South Africa, India, Australia, and New Zealand, but few good data exist on the prevalence in many of these areas. It is rare in black Africans and those Asians of Chinese or Japanese ancestry. Recent data from several European countries suggest that the condition may occur in as many as 1:100 of the population. An upward shift in the age of onset of symptoms has been reported by most countries in the last two decades, and, with few exceptions, it is now less common for CD to present in the very young child. During this same period, the clinical manifestations of CD have changed. Gastrointestinal complaints are still frequent, but nongastrointestinal features are now equally common. The noted change in clinical presentation may be due to some environmental factor or, alternatively, to greater appreciation of the protean nature of the condition. Advances in the Field of CD Serologic tests for CD have been of immense value in the evolution of our understanding of the disease. The tests used measure antibodies to gliadin (AGA), reticulin (ARA), endomysium (EMA), and tissue transglutaminase (tTG). They are primarily used to identify individuals requiring intestinal biopsy for definitive diagnosis, but also may be of value in monitoring response to therapy and dietary compliance. They have played a pivotal role in studies on the prevalence of CD and have been instrumental in our appreciation of the extremely protean manifestations of the condition. Through their use it has become apparent that some individuals remain asymptomatic despite having typical changes of CD on small intestinal biopsy. The therapeutic implications of this discovery are not yet known. It is possible that the complete clinical spectrum of CD has not yet been described, and novel manifestations may be recognized in the future through continued use of serologic screening programs. The ultimate goal remains to develop a serologic test that can replace the intestinal biopsy for definitive diagnosis. Those currently available are unable to do so. The recent discovery that transglutaminase is the main autoantigen recognized by celiac patients may prove to be of fundamental importance in our understanding of the immunopathogenesis of CD. A complete understanding of the immune mechanisms involved in tissue damage is essential if alternative novel therapies for CD are to be developed. Pathogenesis of CD CD is a complex disease involving interactions between genetic and environmental factors. Evidence for a genetic component is both circumstantial and based on specific HLA types. A specific gene abnormality has not yet been identified, and it is probable that more than one is involved. Among the environmental factors implicated in the pathogenesis, prior ingestion of wheat, rye, or barley is an absolute prerequisite to initiate disease in the susceptible individual. Previously oats were also regarded as toxic, but this is now contentious. In vitro and in vivo studies have identified several specific peptides within the α-gliadin molecule that appear capable of initiating disease. The α-gliadin molecule contains a number of repetitive amino acid motifs, and it is probable that multiple peptides within wheat, rye, and barley have toxic potential. The precise relationship between and remains of the that is toxic for patients with CD may our understanding of the that initiate the and to novel therapies for CD. environmental factors have been as a factor for CD in some these is and has been between α-gliadin and be involved in the pathogenesis of CD. The for factors as a factor to disease also an for the in age of onset and clinical it be that is still that or factors are involved. of CD The mucosal damage that CD is to be immune specific immune mechanisms are for the tissue damage or in with a of gliadin on a susceptible remains The precise of is not but of gliadin by the molecule for presentation to the to be a The tissue transglutaminase to an important role in this by the gliadin molecule to increase for the molecule The gliadin also to a for the of with of This is to occur in the intestinal mucosal in patients with CD, but the precise of in mucosal remodeling remains also may a role in the intestinal of antibodies to has been to factor This in intestinal for An understanding of the immune mechanisms that to mucosal in CD is essential if alternative therapies are to be in the for CD the therapy for CD is lifelong adherence to a diet as a that eliminates products containing wheat, rye, and barley. On a clinical and of the intestinal changes on occur within with these an of antibodies to and transglutaminase dietary are These of of a and of and are for of during a celiac In the alternative therapies involving may become of CD of are to with features such as and on and of CD and an for such as intestinal in may individuals with CD greater for autoimmune and to CD are more to With in diagnosis, such may to and of from diagnosis, implications products are more is known the CD has on the of individuals in a strict in these may prove extremely OF The Epidemiology of Celiac CD has The condition is recognized in and young with malabsorption In clinical it is more to identify those with or with nongastrointestinal such as and and and autoimmune in may be by and with a disease and it is first to increase the of of CD and understanding of the role of the diet in do the of individuals who are of wheat, rye, and barley in their be for The of to the prevalence of CD is with clinical disease ranging from to individuals in countries are also of in prevalence within a specific a possible may for these most studies in the were based on clinical and were on the of for CD in the our understanding of the clinical spectrum of CD has in the few decades, and it is that many were not recognized. recent screening studies suggest that the of CD be as as 1:100 throughout as as North and South The disease is also in and It to be very in the black and Japanese studies on the prevalence of CD have been by small and and it is still possible that between do the prevalence of CD in many is most it is throughout the and that the is or in a of the population The of CD is known the of CD. It is that who to ingest develop small intestinal mucosal changes and symptoms. this may not be are known in ingestion in genetically susceptible individuals has clinical disease mucosal it is possible that some individuals through symptoms or despite having mucosal as the prevalence of CD in a population is of the is for of CD may have to be in the and the of have to be and can such as and or autoimmune CD screening of the population be on the of such screening are but CD most of the World for disease an for the condition. a and specific means is available of by of The is a test and and of to is an test and not With in the this may prove to be the most test for population The of Celiac A genetic is to be important in the development of CD in response to to gliadin This was first recognized by an prevalence of CD and a of in The role of HLA in CD has been more and it is now also apparent that are involved. of the genetic factors for CD is essential for our understanding of the pathogenesis of the condition and has implications for future and was first with HLA and both and the HLA association found has been of occurs in of individuals with CD with of with CD that are most have the and this may be the for CD in some such the groups in is in with the with the of is with for CD, and this is when with peptides and with to the molecule by in vitro but to gliadin that is has not yet been It is possible that and both as for presentation of gliadin peptides to gliadin peptides containing glutamine to with the may present peptides that have not been by present the association between and CD, the of specific HLA not the development of CD, and less than of have the condition. the for CD is in than for that that are not by These that factors in CD are in or more are to be of with the of the HLA on of gene have been in identifying The most recent not gene with CD in but implicated the of and These may be to in the or to the that from were in the with is on in CD. with CD were found to have amino acid of the genetic factors for data are available of the amino acid of the or of gliadin for has found with CD. is on and to with to The gene has been as one of the disease for the autoimmune and and has been implicated in CD. of with CD, and in patients with CD have a possible for CD in the gene was of or association between CD and the test in and CD is to be an small intestinal features suggest both and the precise of to the characteristic mucosal changes is still A complete understanding of these is essential and has important implications for both and therapy in the the that of by is the by studies have identified recognized by by from and two from the in a and two by from α-gliadin and one from and for the α-gliadin for are by of glutamine and that increase to Recent studies have identified an CD specific the same identified by These provide a for future to of the with and of is in biopsy from CD are to in with and more than in patients with In vitro of mucosal from CD patients found in of and have been but significantly after in vitro from mucosal after in vitro are with a by An of HLA and response from and by mucosal and An important of CD is the of the small intestinal mucosal by than of these intraepithelial lymphocytes and less than In mucosal the of or the of the In the celiac the of is in both and The role of remains but their may be to the of by such is due to by during The that more than their and the more increase of in response to that the in the population. of this population be by or by It is to the possible role the within such a population. have and a that and and an important role in the of mucosal damage The celiac produces characteristic mucosal is of due to and an of in the The be due to of factor by It is possible that to in to by are to increase of by and that be for the mucosal CD is with is the of tissue transglutaminase and as It has been that provide for the of but the precise of to remains of the mechanisms involved not our understanding of the pathogenesis of CD but provide features of autoimmune in has been the immune-mediated in CD, a number of important still to be These The for the of to gliadin in CD and the role in this of the gliadin for and of of the gliadin molecule are for a in the pathogenesis of the celiac are due to or is also a of on the from an in vitro have an with to of and in vivo of within a a very may initiate the to response in the of the mucosal response is and maintained in CD. but small of have been found in biopsy from may still a and are for such a in the It is also possible that a of on the of that of The mechanisms and the role of in the pathogenesis of the mucosal damage The nature of the mechanisms involved in the pathogenesis of the mucosal with on the involved in mucosal remodeling a role in the pathogenesis of the mucosal damage as by their on in vitro of or their is an are by gliadin is also of such may be of in understanding some of the clinical manifestations of the disease. The of Celiac The clinical spectrum of CD has in the last and is than with few exceptions, has been an upward shift in the age of onset of symptoms reported this same New has been to some of the novel but these are used in An appreciation of the protean manifestations of CD and of is essential to and our understanding of the factors involved in symptoms. The clinical manifestations of CD are in The presentation in than of age is to as the and was the most common recognized of CD. With few this is now less and in most countries onset of symptoms is not in or Gastrointestinal symptoms are still common but may be or It is now as common for the symptoms to be nongastrointestinal in is in clinical and the nongastrointestinal manifestations in can occur in or various CD has been found in of for and in to of those with of with have characteristic to small intestinal most of the have mucosal and may be present in to of with CD, and serologic screening for CD in with has identified the condition in manifestations of for the change in clinical spectrum are not of of dietary in the and of and an of of CD with for of the the in clinical presentation and develop a of for the condition. may be in and with and are of of to the in the and of CD can to and CD is with the in A number of these are autoimmune to of patients with or have characteristic changes of CD on small intestinal biopsy. This may be as screening of such patients a of has identified some with CD who serologic of patients with CD have is than in the and the prevalence of CD in is between and patients with these have symptoms of CD the of diagnosis, and with a has on the condition. is also that these are to CD. is a that autoimmune are less in those individuals in the and of CD occurs a young The precise of this clinical remains to be with with CD screening has identified a number of individuals with apparent symptoms despite typical changes on small intestinal biopsy. This occurs in to of of CD and studies involving a number of have that asymptomatic were more than those with symptoms. The of this has yet to be but it have important and therapeutic A number of have been to some of the recognized clinical in CD These for and and for various clinical The are not used in the same and is for in is used to those manifestations of CD that are not in nature manifestations are as common as those of a nature and be regarded as CD to those individuals who are asymptomatic but have characteristic small intestinal mucosal changes that on a individuals are identified through screening some of these individuals in or were not and the CD is more for this CD to those with celiac for but on small intestinal biopsy. a of have to typical mucosal changes in a small number of these It is not known celiac develop mucosal changes or become CD to individuals who are asymptomatic with a biopsy on a diet, but who some or an biopsy that on a The clinical of this is The biopsy may a due to the nature of the in the It is also known that after recovery on a some individuals with CD can a diet for a of these individuals may of a the therapeutic that are by these clinical it is essential that be used in future The of Celiac The of CD be as requires lifelong adherence to a present this requires of a small intestinal biopsy. features on to of the crypt of intraepithelial lymphocytes with a of and in the of with of the and of an and in the The changes are with an by crypt hyperplasia and is crypt hyperplasia and the can be with it is less when of are a in asymptomatic individuals biopsy for of serologic screening tests a therapeutic for the of CD by in a of the first to on a diet, the to on a and the to after a In the for these on their it was that when is a clinical and and are not in most In the features of CD can be with that occur in this age and and, are still in this These are the of that two be a characteristic small intestinal mucosal abnormality on be clinical on a with of symptoms. the of with on a to the the are for most are when and are These in biopsy was of in the is in patients on a changes on or an biopsy patients who are with the or who their and to the and asymptomatic individuals through screening programs. with characteristic mucosal damage found during for a condition with CD not a is it be of age to the for and it not be during of such as means of patients to on a to the or a diet that the of to of bread of wheat to the for of the dietary is the onset of clinical or between and in the of symptoms. the biopsy remains is essential and clinical may not occur for several of CD in these may be of symptoms with CD or of tests that were on a are for small intestinal CD Serologic Serologic tests are most for screening Those available by and by and by The has a and but is an and be in those with occurs in of with the test is with for both and in It may also be less reliable in than of of recognized as the main autoantigen for may replace as the test of studies good between and and in the may this is based on an and has less for Serologic tests are for those for CD. This individuals with symptoms of CD with CD and asymptomatic of a CD of the population is not yet This may change with future data and studies the of and of CD onset of symptoms. of CD of CD by means than an intestinal biopsy remains an serologic tests are not to be for this A to be is use of serologic tests in with HLA of the and The of a characteristic clinical presentation with HLA and complete resolution of symptoms on a may be for a in some a be the studies have been to The Treatment of Celiac adherence to a is the for CD The of both within and between or a of by some wheat and and some the for to of is and many countries have or is for on this Treatment of patients with CD be on a diet that products containing wheat, rye, and barley. oats are is In the wheat, rye, and barley are more than rye, and barley have a to of than oats to and greater that oats may not be studies oats as toxic on clinical and fat and Recent studies and serologic tests a to showed when oats were to the of patients or those on an this the that oats are are still a number of studies to have been in have and have not available oats may be with wheat and in the or is for oats to be On it to ingestion of oats are of studies and are to the of Treatment of Serologic screening studies have identified individuals with characteristic small intestinal mucosal changes but apparent symptoms. to one asymptomatic may patients by as many as The and therapeutic implications of this remain to be asymptomatic individuals on a that features of and are not recognized is such from a data that asymptomatic individuals do so. of CD an for and and studies the for is by adherence to a can be improved in with CD after on a and is in those and in In asymptomatic the features of CD in the small are the same as in those with symptoms. it to that asymptomatic individuals with have the same as those with symptoms and be to a It is less those with CD but biopsy or with changes such as an increase in are and be to a these therapeutic the to be the prevalence of asymptomatic individuals with CD, the of not asymptomatic and the of or those with who to more in to genetically wheat and it it may be possible to in vivo or during the to this it is first to identify the toxic It is that multiple peptides in the gliadin molecule are capable of CD, and wheat protein may prove therapies to in the by are also in this is on a complete understanding of the and involved in the pathogenesis of CD. has been CD in the two decades, but a of is to the of the condition. have to this by that be to provide for may prove to be a of the population. to these studies in both the clinical and with collaboration an for The that are not but are to some of the most important The Epidemiology of Celiac a serologic screening test for use in is currently the most and specific test but it is and The test the most of as to for may be studies are to the test and and of the in of CD patients and more data on the prevalence of CD in studies to of the population are These both and of be in and be by an the for the of CD. based primarily on biopsy may be an from the to the and for the data on the of and CD. This on diagnosis, and The of Celiac for genetic factors. of the involved and their association with specific HLA may in clinical of CD and identify that in involving of may identify more than one gene tests for association may prove studies increase the number of available The Pathogenesis of Celiac recognized by intestinal in celiac as as and be use and HLA be by in vivo the role of in the of recognized by the of this and the of the role of and in the of mucosal studies to gliadin has a on the mucosal the spectrum of by dietary in celiac the mechanisms to of and the role of antibodies to in the pathogenesis of mucosal in vitro be for this the and involved in the mucosal remodeling in CD intestinal the that are after with This may to of to CD. for CD. This of therapies based on in the The of Celiac on in CD. of in a to on from of the The be and published by the more data on the clinical spectrum of CD in These studies be with those the prevalence of CD and genetic factors. of involving both and of are The with and CD to be to for and in the data on environmental factors that may on the clinical presentation of CD. data on of and and of ingestion to their on the age of onset and clinical manifestations of CD. for this be studies on prevalence and clinical and of CD the for future onset of autoimmune studies involving identified through screening and and of of those in was in childhood with those or The of Celiac the relationship between features and disease. patients with with a for This may not to those with changes such as an increase in studies with and groups in those who have an increase in the for and This to of age and those of age with CD. studies with are to alternative to the in these studies to typical biopsy changes a of HLA and in a very young or typical biopsy changes with of in is for a diagnosis. for diagnosis. studies to specific clinical with serologic characteristic HLA complete resolution of symptoms on a is to a diagnosis. of specific with CD in the future may this The Treatment of Celiac a for the on a based on with the and and celiac to on for a for and of CD and as for of in the of oats studies with in both and and both patients and those on a be a of the and of for individuals with CD. of a number of such those a to those that do the and of for individuals with CD. of a number of such to or to alternative of This is on identifying specific peptides that cause CD in the genetically susceptible and the of that in mucosal In autoimmune appear to have a genetic component and an environmental factor to initiate clinical disease. The of CD a to this on the is and a specific environmental factor has been identified when in complete resolution of the disease with of the of CD has implications that those who have the condition. our of it is essential that be on studies both a and clinical of a to initiate this is as a first this
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hill et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: